Cellid, Co., Ltd. (KOSDAQ:299660)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,534.00
+128.00 (9.10%)
Jul 1, 2026, 3:30 PM KST
Market Cap41.48B -72.9%
Revenue (ttm)n/a
Net Incomen/a
EPSn/a
Shares Out 29.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,494,756
Open1,420.00
Previous Close1,406.00
Day's Range1,411.00 - 1,591.00
52-Week Range1,369.00 - 5,190.00
Beta1.39
Analystsn/a
Price Targetn/a
Earnings Daten/a

About Cellid,

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2006
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 299660
Full Company Profile

Financial Performance

Financial Statements